tradingkey.logo

Nexalin Technology Inc

NXL
查看詳細走勢圖
0.832USD
+0.026+3.29%
收盤 12/19, 16:00美東報價延遲15分鐘
15.13M總市值
虧損本益比TTM

Nexalin Technology Inc

0.832
+0.026+3.29%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+3.29%

5天

-9.60%

1月

-15.29%

6月

-20.03%

今年開始到現在

-69.87%

1年

-68.38%

查看詳細走勢圖

TradingKey Nexalin Technology Inc股票評分

單位: USD 更新時間: 2025-12-19

操作建議

Nexalin Technology Inc當前公司基本面數據相對非常健康,增長潛力穩定。當前估值合理,在醫療設備與耗材行業排名122/208位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價4.00。中期看,股價處於下降通道。近一個月,市場表現非常差,但技術面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Nexalin Technology Inc評分

相關信息

行業排名
122 / 208
全市場排名
289 / 4582
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 1 分析師
買入
評級
4.000
目標均價
+316.41%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Nexalin Technology Inc亮點

亮點風險
Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
業績增長期
公司處於發展階段,最新年度總收入168.72K美元
利潤高增長
公司淨利潤處於行業前列,最新年度總收入168.72K美元
估值合理
公司最新PE估值-1.29,處於3年歷史合理位
機構加倉
最新機構持股1.33M股,環比增加34.88%
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉,最新持倉55.70K股
活躍度增加
近期活躍度增加,過去20天平均換手率1.05

Nexalin Technology Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Nexalin Technology Inc簡介

Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
公司代碼NXL
公司Nexalin Technology Inc
CEOWhite (Mark)
網址https://nexalin.com

常見問題

Nexalin Technology Inc(NXL)的當前股價是多少?

Nexalin Technology Inc(NXL)的當前股價是 0.832。

Nexalin Technology Inc 的股票代碼是什麼?

Nexalin Technology Inc的股票代碼是NXL。

Nexalin Technology Inc股票的52週最高點是多少?

Nexalin Technology Inc股票的52週最高點是3.870。

Nexalin Technology Inc股票的52週最低點是多少?

Nexalin Technology Inc股票的52週最低點是0.702。

Nexalin Technology Inc的市值是多少?

Nexalin Technology Inc的市值是15.13M。

Nexalin Technology Inc的淨利潤是多少?

Nexalin Technology Inc的淨利潤為-7.61M。

現在Nexalin Technology Inc(NXL)的股票是買入、持有還是賣出?

根據分析師評級,Nexalin Technology Inc(NXL)的總體評級為買入,目標價格為4.000。

Nexalin Technology Inc(NXL)股票的每股收益(EPS TTM)是多少

Nexalin Technology Inc(NXL)股票的每股收益(EPS TTM)是-0.645。
KeyAI